BRIEF—Mundipharma to market Aloxi in Vietnam

Mundipharma and Helsinn Group signed a licensing and distribution agreement for the anti-emetic agent Aloxi (palonosetron) in Vietnam, extending an international collaboration.

Aloxi, a 5-HT3 receptor antagonist, has already been approved in Vietnam.

Chemotherapy-induced nausea and vomiting (CINV) is one of the most common and distressing side effects of cancer chemotherapy.

Mundipharma and Helsinn are experts in the CINV field with decades of shared experience and are currently providing medicine to CINV sufferers.

Mundipharma chief executive Raman Singh said: “This important extension of our portfolio in Vietnam offers relief to patients suffering from the side effects of chemotherapy and enables patients and healthcare providers to benefit from our expertise in this area.”

“Helsinn and Mundipharma have an effective, longstanding partnership and Mundipharma successfully markets, promotes and distributes a number of our products across a range of territories. We’re delighted to be able to extend this relationship through this agreement,” added Helsinn group vice chairman and CEO Riccardo Braglia.